Enhanced Recovery After Surgery in the Patients With Hepatocellular Carcinoma Undergoing Hemihepatectomy

• Published in: Surgical innovation p. 15533506211057628
• Main Authors: Zhou, Jiamin, He, Xigan, Wang, Miao, Zhao, Yiming, Wang, Longrong, Mao, Anrong, Wang, Lu
• Format: Journal Article
• Language: English
• Published: United States 01.12.2022
• Subjects: Enhanced recovery after surgery; low-molecular-weight heparin; hemihepatectomy; hepatocellular carcinoma; liver function
• ISSN: 1553-3514
• DOI: 10.1177/15533506211057628

This study aims to compare the effectiveness and safety of enhanced recovery after surgery (ERAS) in patients with hepatocellular carcinoma (HCC) undergoing hemihepatectomy. From January 2017 to June 2019, 54 and 56 patients were enrolled into the control and ERAS group, retrospectively. All the indicators related to operation, liver functions, and postoperative outcomes were included in the analysis. Propensity score matching (PSM) analysis identified 72 patients for further analysis. The clinicopathological characteristics were well-matched after PSM, and there were no significant differences in the operative duration, blood loss, blood transfusion, hospital costs, and most postoperative indicators in these 2 groups. In the ERAS group, D-dimer and fibrin degradation product values were significantly reduced (3.57 (2.874.60) μg/ml vs 4.81 (3.948.29) μg/ml and 11.90 (10.0418.02) μg/ml vs 15.80 (11.5529.24) μg/ml; = .002 and = .023, respectively). The days that semiliquid diet was allowed after surgery (2.00 (2.003.00) days vs 5.00 (4.006.00) days, < .001), abdominal drainage tube indwelling duration (5.00 (4.005.00) days vs 5.00 (4.756.25) days, = .004), and hospital stay after surgery (6.00 (6.007.00) days vs 8.00 (7.0010.00) days, < .001) were also significantly shorter. The proportion of patients requiring analgesic treatment was significantly lower in the postoperative day 2 and day 4 ( < .001 and = .025, respectively). The morbidity was significantly less (36.11% vs 69.44%, = .005). ERAS programs are feasible and safe in HCC patients undergoing hemihepatectomy. Postoperative anticoagulant therapy may be one of the necessary steps.